BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gunturu KS, Yao X, Cong X, Thumar JR, Hochster HS, Stein SM, Lacy J. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol 2013;30. [DOI: 10.1007/s12032-012-0361-2] [Cited by in Crossref: 89] [Cited by in F6Publishing: 88] [Article Influence: 8.9] [Reference Citation Analysis]
Number Citing Articles
1 Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Koerkamp BG. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17:801-810. [PMID: 27160474 DOI: 10.1016/s1470-2045(16)00172-8] [Cited by in Crossref: 416] [Cited by in F6Publishing: 193] [Article Influence: 69.3] [Reference Citation Analysis]
2 Mohammed A, Janakiram NB, Pant S, Rao CV. Molecular Targeted Intervention for Pancreatic Cancer. Cancers (Basel) 2015;7:1499-542. [PMID: 26266422 DOI: 10.3390/cancers7030850] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
3 Thibodeau S, Voutsadakis IA. FOLFIRINOX Chemotherapy in Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis of Retrospective and Phase II Studies. J Clin Med 2018;7:E7. [PMID: 29300345 DOI: 10.3390/jcm7010007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
4 Motomura M, Ichihara H, Matsumoto Y. Nano-chemotherapy using cationic liposome that strategically targets the cell membrane potential of pancreatic cancer cells with negative charge. Bioorganic & Medicinal Chemistry Letters 2018;28:1161-5. [DOI: 10.1016/j.bmcl.2018.03.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
5 Sugimoto M, Takagi T, Suzuki R, Konno N, Asama H, Sato Y, Irie H, Okubo Y, Nakamura J, Takasumi M, Hashimoto M, Kato T, Kobashi R, Hikichi T, Ohira H. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients. BMC Cancer 2021;21:1319. [PMID: 34886831 DOI: 10.1186/s12885-021-09069-9] [Reference Citation Analysis]
6 Baldini C, Escande A, Bouché O, El Hajbi F, Volet J, Bourgeois V, Renaut Vantroys T, Ploquin A, Desauw C, Hebbar M. Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis. Pancreatology 2017;17:146-9. [PMID: 28040425 DOI: 10.1016/j.pan.2016.12.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
7 Bittoni A, Santoni M, Lanese A, Pellei C, Andrikou K, Stefano C. Neoadjuvant therapy in pancreatic cancer: an emerging strategy. Gastroenterol Res Pract 2014;2014:183852. [PMID: 25101123 DOI: 10.1155/2014/183852] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
8 Goel G, Sun W. Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol. 2015;8:44. [PMID: 25935754 DOI: 10.1186/s13045-015-0141-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
9 Rubinson DA, Wolpin BM. Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am 2015;29:761-76. [PMID: 26226909 DOI: 10.1016/j.hoc.2015.04.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
10 Mohammad AA. Advanced pancreatic cancer: The standard of care and new opportunities. Oncol Rev 2018;12:370. [PMID: 30344961 DOI: 10.4081/oncol.2018.370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
11 Berger AK, Haag GM, Ehmann M, Byl A, Jäger D, Springfeld C. Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient. BMC Gastroenterol 2017;17:143. [PMID: 29207968 DOI: 10.1186/s12876-017-0709-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
12 Muranaka T, Kuwatani M, Komatsu Y, Sawada K, Nakatsumi H, Kawamoto Y, Yuki S, Kubota Y, Kubo K, Kawahata S. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. J Gastrointest Oncol. 2017;8:566-571. [PMID: 28736643 DOI: 10.21037/jgo.2017.02.02] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 7.2] [Reference Citation Analysis]
13 Varadhachary GR, Wolff RA. Current and Evolving Therapies for Metastatic Pancreatic Cancer: Are We Stuck With Cytotoxic Chemotherapy? J Oncol Pract 2016;12:797-805. [PMID: 27621332 DOI: 10.1200/JOP.2016.015586] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
14 Mancini BR, Stein S, Lloyd S, Rutter CE, James E, Chang BW, Lacy J, Johung KL. Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer. J Gastrointest Oncol 2018;9:982-8. [PMID: 30603116 DOI: 10.21037/jgo.2018.04.03] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
15 Karim S, Zhang-Salomans J, Biagi JJ, Asmis T, Booth CM. Uptake and Effectiveness of FOLFIRINOX for Advanced Pancreatic Cancer: a Population-based Study. Clin Oncol (R Coll Radiol) 2018;30:e16-21. [PMID: 29137884 DOI: 10.1016/j.clon.2017.10.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
16 García-Reyes B, Kretz AL, Ruff JP, von Karstedt S, Hillenbrand A, Knippschild U, Henne-Bruns D, Lemke J. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2018;19:E3219. [PMID: 30340359 DOI: 10.3390/ijms19103219] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
17 Chllamma MK, Cook N, Dhani NC, Giby K, Dodd A, Wang L, Hedley DW, Moore MJ, Knox JJ. FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. Br J Cancer. 2016;115:649-654. [PMID: 27467054 DOI: 10.1038/bjc.2016.222] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
18 Usón Junior PLS, Rother ET, Maluf FC, Bugano DDG. Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic Pancreatic Cancer. Clin Colorectal Cancer 2018;17:187-97. [PMID: 29615310 DOI: 10.1016/j.clcc.2018.03.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
19 Leen E, Picard J, Stebbing J, Abel M, Dhillon T, Wasan H. Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma. J Gastrointest Oncol. 2018;9:275-281. [PMID: 29755766 DOI: 10.21037/jgo.2018.01.14] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
20 Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Aitini E, Barni S. FOLFIRINOX-Based Neoadjuvant Therapy in Borderline Resectable or Unresectable Pancreatic Cancer: A Meta-Analytical Review of Published Studies. Pancreas 2015;44:515-21. [DOI: 10.1097/mpa.0000000000000314] [Cited by in Crossref: 126] [Cited by in F6Publishing: 46] [Article Influence: 18.0] [Reference Citation Analysis]
21 Bressand D, Novell A, Girault A, Raoul W, Fromont-hankard G, Escoffre J, Lecomte T, Bouakaz A. Enhancing Nab-Paclitaxel Delivery Using Microbubble-Assisted Ultrasound in a Pancreatic Cancer Model. Mol Pharmaceutics 2019;16:3814-22. [DOI: 10.1021/acs.molpharmaceut.9b00416] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
22 Boland AJ, O'Kane AA, Buick R, Longley DB, Scott CJ. Antibody therapy in pancreatic cancer: mAb-ye we're onto something? Biochim Biophys Acta Rev Cancer 2021;1876:188557. [PMID: 33945846 DOI: 10.1016/j.bbcan.2021.188557] [Reference Citation Analysis]
23 Martín AM, Hidalgo M, Alvarez R, Arrazubi V, Martínez-Galán J, Salgado M, Macarulla T, Carrato A. From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. J Cancer 2018;9:1978-88. [PMID: 29896283 DOI: 10.7150/jca.23716] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
24 Nitsche U, Wenzel P, Siveke JT, Braren R, Holzapfel K, Schlitter AM, Stöß C, Kong B, Esposito I, Erkan M, Michalski CW, Friess H, Kleeff J. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience. Ann Surg Oncol 2015;22 Suppl 3:S1212-20. [PMID: 26350368 DOI: 10.1245/s10434-015-4851-2] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 7.9] [Reference Citation Analysis]
25 Valsecchi ME, Díaz-Cantón E, de la Vega M, Littman SJ. Recent treatment advances and novel therapies in pancreas cancer: a review. J Gastrointest Cancer 2014;45:190-201. [PMID: 24343588 DOI: 10.1007/s12029-013-9561-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
26 Bhattacharjee V, Zhou Y, Yen TJ. A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells. Cell Cycle 2014;13:3839-56. [PMID: 25558828 DOI: 10.4161/15384101.2014.967070] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
27 Frappart PO, Hofmann TG. Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine. Cancers (Basel) 2020;12:E2750. [PMID: 32987786 DOI: 10.3390/cancers12102750] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
28 Khushman M, Dempsey N, Cudris Maldonado J, Loaiza-bonilla A, Velez M, Carcas L, Dammrich D, Hurtado-cordovi J, Parajuli R, Pollack T, Harwood AP, Macintyre J, Tzeng CD, Merchan JR, Restrepo MH, Akunyili II, Ribeiro A, Narayanan G, Portelance L, Sleeman D, Levi JU, Rocha Lima CM, Hosein PJ. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Pancreatology 2015;15:667-73. [DOI: 10.1016/j.pan.2015.08.010] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 7.7] [Reference Citation Analysis]
29 Xu X, Wu Q, Wang Z, Zheng S, Ge K, Jia C. Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer. Clin Exp Med 2019;19:149-57. [PMID: 30498929 DOI: 10.1007/s10238-018-0540-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
30 Gostimir M, Bennett S, Moyana T, Sekhon H, Martel G. Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review. BMC Cancer 2016;16:786. [PMID: 27724927 DOI: 10.1186/s12885-016-2821-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
31 Chen Z, Lv Y, Li H, Diao R, Zhou J, Yu T. Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer. Medicine (Baltimore) 2021;100:e24068. [PMID: 33546009 DOI: 10.1097/MD.0000000000024068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
32 Chalabi-Dchar M, Cruz E, Mertani HC, Diaz JJ, Courty J, Cascone I, Bouvet P. Nucleolin Aptamer N6L Reprograms the Translational Machinery and Acts Synergistically with mTORi to Inhibit Pancreatic Cancer Proliferation. Cancers (Basel) 2021;13:4957. [PMID: 34638443 DOI: 10.3390/cancers13194957] [Reference Citation Analysis]
33 Matsuoka A, Maeda O, Inada-Inoue M, Ohno E, Hirooka Y, Yokoyama Y, Fujii T, Nagino M, Goto H, Ando Y. FOLFIRINOX-induced reversible dysarthria: A case report and review of previous cases. Oncol Lett 2015;10:2662-4. [PMID: 26622908 DOI: 10.3892/ol.2015.3591] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
34 Bates SE, Fojo T. New drug for pancreatic cancer highlights the dual effect of regulatory approvals. Nat Rev Clin Oncol 2016;13:205-6. [DOI: 10.1038/nrclinonc.2016.22] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
35 Rombouts S, Walma M, Vogel JA, Rijssen Lv, Wilmink J, Mohammad NH, Santvoort Hv, Molenaar IQ, Besselink MG Systematic review of resection rates and clinical outcomes after FOLFIRINOX-based treatment in patients with locally advanced pancreatic cancer. American Society of Clinical Oncology Annual Meeting. 2016;suppl: abstr 4115. [PMID: 27370653 DOI: 10.1245/s10434-016-5373-2] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 13.2] [Reference Citation Analysis]
36 Nitipir C, Vrabie R, Parosanu AI, Tulin R, Cretu B, Cursaru A, Slavu I, Miron A, Calu V, Orlov Slavu MC. Clinical Impact of the Administration of FOLFIRINOX Beyond Six Months in Advanced Pancreatic Adenocarcinoma: A Cohort Study. Cureus 2021;13:e19361. [PMID: 34925974 DOI: 10.7759/cureus.19361] [Reference Citation Analysis]
37 Heinemann V, Haas M, Boeck S. Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Ann Oncol. 2013;24:2484-2492. [PMID: 23852311 DOI: 10.1093/annonc/mdt239] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 8.7] [Reference Citation Analysis]
38 McKeague M, Wang YH, Smolke CD. In Vitro Screening and in Silico Modeling of RNA-Based Gene Expression Control. ACS Chem Biol 2015;10:2463-7. [PMID: 26359915 DOI: 10.1021/acschembio.5b00518] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
39 Cheema AR, O’reilly EM. Management of Metastatic Pancreatic Adenocarcinoma. Surgical Clinics of North America 2016;96:1391-414. [DOI: 10.1016/j.suc.2016.07.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
40 Pollom EL, Koong AC, Ko AH. Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am 2015;29:741-59. [PMID: 26226908 DOI: 10.1016/j.hoc.2015.04.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
41 Valeri S, Borzomati D, Nappo G, Perrone G, Santini D, Coppola R. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature. Pancreatology. 2014;14:425-430. [PMID: 25278312 DOI: 10.1016/j.pan.2014.07.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
42 Palmarocchi MC, Balzarotti Canger RC, Saletti P. Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report. Oncol Lett 2017;13:4445-52. [PMID: 28588713 DOI: 10.3892/ol.2017.6026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
43 Schwarz L, Vernerey D, Bachet JB, Tuech JJ, Portales F, Michel P, Cunha AS. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study). BMC Cancer 2018;18:762. [PMID: 30041614 DOI: 10.1186/s12885-018-4663-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
44 Polistina F, Natale GD, Bonciarelli G, Ambrosino G, Frego M. Neoadjuvant strategies for pancreatic cancer. World J Gastroenterol 2014; 20(28): 9374-9383 [PMID: 25071332 DOI: 10.3748/wjg.v20.i28.9374] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
45 Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015;12:319-334. [PMID: 25824606 DOI: 10.1038/nrclinonc.2015.53] [Cited by in Crossref: 350] [Cited by in F6Publishing: 325] [Article Influence: 50.0] [Reference Citation Analysis]
46 Zhen DB, McDevitt RL, Zalupski MM, Sahai V. Irinotecan-associated dysarthria: A single institution case series with management implications in patients with gastrointestinal malignancies. J Oncol Pharm Pract 2019;25:980-6. [PMID: 29562843 DOI: 10.1177/1078155218763044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
47 Elbeddini A, Hooda N, Gazarin M, Webster P, McMillan J. Irinotecan-Associated Dysarthria in Patients with Pancreatic Cancer: A Single Site Experience. Am J Case Rep 2020;21:e924058. [PMID: 32594093 DOI: 10.12659/AJCR.924058] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Ho MY, Kennecke HF, Renouf DJ, Cheung WY, Lim HJ, Gill S. Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study. Am J Clin Oncol. 2015; Jul 9; Epub ahead of print. [PMID: 26165420 DOI: 10.1097/coc.0000000000000205] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
49 Combs SE. Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factors. Langenbecks Arch Surg 2015;400:749-56. [DOI: 10.1007/s00423-015-1309-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
50 Lee RC, Kanhere H, Trochsler M, Broadbridge V, Maddern G, Price TJ. Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases? World J Gastrointest Oncol 2018; 10(8): 211-220 [PMID: 30147847 DOI: 10.4251/wjgo.v10.i8.211] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
51 Lambert A, Gavoille C, Conroy T. Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions. Therap Adv Gastroenterol 2017;10:631-45. [PMID: 28835777 DOI: 10.1177/1756283X17713879] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
52 Marthey L, Sa-Cunha A, Blanc JF, Gauthier M, Cueff A, Francois E, Trouilloud I, Malka D, Bachet JB, Coriat R. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol. 2015;22:295-301. [PMID: 25037971 DOI: 10.1245/s10434-014-3898-9] [Cited by in Crossref: 101] [Cited by in F6Publishing: 99] [Article Influence: 12.6] [Reference Citation Analysis]
53 Cavanna L, Stroppa EM, Citterio C, Mordenti P, Di Nunzio C, Peveri S, Orlandi E, Vecchia S. Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience. Onco Targets Ther. 2019;12:3077-3085. [PMID: 31118666 DOI: 10.2147/ott.s200754] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
54 Peng W, Zhang J, Liu J. URG11 predicts poor prognosis of pancreatic cancer by enhancing epithelial-mesenchymal transition-driven invasion. Med Oncol 2014;31:64. [PMID: 24930007 DOI: 10.1007/s12032-014-0064-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
55 He M, Sun J, Zhao D, He H, Wang B, Xu L, Shang Y, Ren S, Zhang Y, Wu T. Modified-FOLFIRINOX combined with deep regional hyperthermia in pancreatic cancer: a retrospective study in Chinese patients.Int J Hyperthermia. 2019;36:394-402. [PMID: 30917701 DOI: 10.1080/02656736.2019.1579371] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
56 Ulusakarya A, Teyar N, Karaboué A, Haydar M, Krimi S, Biondani P, Gumus Y, Chebib A, Almohamad W, Morère JF. Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma. Medicine (Baltimore) 2019;98:e15341. [PMID: 31008993 DOI: 10.1097/MD.0000000000015341] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
57 Moorcraft SY, Khan K, Peckitt C, Watkins D, Rao S, Cunningham D, Chau I. FOLFIRINOX for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: The Royal Marsden Experience. Clinical Colorectal Cancer 2014;13:232-8. [DOI: 10.1016/j.clcc.2014.09.005] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
58 Papneja N, Zaidi A, Chalchal H, Moser M, Tan K, Olson C, Haider K, Shaw J, Ahmed S. Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study. Pancreas 2019;48:920-6. [PMID: 31180981 DOI: 10.1097/MPA.0000000000001340] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
59 Cid-Arregui A, Juarez V. Perspectives in the treatment of pancreatic adenocarcinoma. World J Gastroenterol 2015; 21(31): 9297-9316 [PMID: 26309356 DOI: 10.3748/wjg.v21.i31.9297] [Cited by in CrossRef: 83] [Cited by in F6Publishing: 74] [Article Influence: 11.9] [Reference Citation Analysis]
60 Mohammed S, II GVB, Fisher WE. Pancreatic cancer: Advances in treatment. World J Gastroenterol 2014; 20(28): 9354-9360 [PMID: 25071330 DOI: 10.3748/wjg.v20.i28.9354] [Cited by in F6Publishing: 71] [Reference Citation Analysis]
61 Collins DC, Morris PG. Systemic therapy for advanced pancreatic cancer: individualising cytotoxic therapy. Expert Opinion on Pharmacotherapy 2015;16:851-61. [DOI: 10.1517/14656566.2015.1024654] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
62 Papadatos-Pastos D, Thillai K, Rabbie R, Ross P, Sarker D. FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer. Expert Rev Anticancer Ther. 2014;14:1115-1125. [PMID: 25204327 DOI: 10.1586/14737140.2014.957188] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
63 Taieb J, Pointet AL, Van Laethem JL, Laquente B, Pernot S, Lordick F, Reni M. What treatment in 2017 for inoperable pancreatic cancers? Ann Oncol. 2017;28:1473-1483. [PMID: 28459988 DOI: 10.1093/annonc/mdx174] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
64 Chiorean EG, Coveler AL. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther. 2015;9:3529-3545. [PMID: 26185420 DOI: 10.2147/DDDT.S60328] [Cited by in Crossref: 74] [Cited by in F6Publishing: 48] [Article Influence: 10.6] [Reference Citation Analysis]
65 Wang C, Liu X, Wang X, Wang Y, Cha N. Effects of chemoradiotherapy and chemotherapy on survival of patients with locally advanced pancreatic cancer: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2018;97:e12260. [PMID: 30200163 DOI: 10.1097/MD.0000000000012260] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
66 Katz MH, Landry J, Kindler HL. Current controversies in the stage-specific multidisciplinary management of pancreatic cancer. Am Soc Clin Oncol Educ Book. 2014;e157-e164. [PMID: 24857097 DOI: 10.14694/edbook_am.2014.34.e157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
67 Oba A, Ho F, Bao QR, Al-Musawi MH, Schulick RD, Del Chiaro M. Neoadjuvant Treatment in Pancreatic Cancer. Front Oncol. 2020;10:245. [PMID: 32185128 DOI: 10.3389/fonc.2020.00245] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 14.5] [Reference Citation Analysis]
68 Andrikou K, Peterle C, Pipitone S, Salati M, Cascinu S. Emerging antibodies for the treatment of pancreatic cancer. Expert Opinion on Emerging Drugs 2016;22:39-51. [DOI: 10.1080/14728214.2017.1293649] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
69 Stein SM, James ES, Deng Y, Cong X, Kortmansky JS, Li J, Staugaard C, Indukala D, Boustani AM, Patel V, Cha CH, Salem RR, Chang B, Hochster HS, Lacy J. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer. 2016;114:737-743. [PMID: 27022826 DOI: 10.1038/bjc.2016.45] [Cited by in Crossref: 99] [Cited by in F6Publishing: 94] [Article Influence: 16.5] [Reference Citation Analysis]
70 He J, Page AJ, Weiss M, Wolfgang CL, Herman JM, Pawlik TM. Management of borderline and locally advanced pancreatic cancer: Where do we stand? World J Gastroenterol 2014; 20(9): 2255-2266 [PMID: 24605025 DOI: 10.3748/wjg.v20.i9.2255] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
71 Brayshaw LL, Martinez-Fleites C, Athanasopoulos T, Southgate T, Jespers L, Herring C. The role of small molecules in cell and gene therapy. RSC Med Chem 2021;12:330-52. [PMID: 34046619 DOI: 10.1039/d0md00221f] [Reference Citation Analysis]
72 Vaccaro V, Sperduti I, Vari S, Bria E, Melisi D, Garufi C, Nuzzo C, Scarpa A, Tortora G, Cognetti F, Reni M, Milella M. Metastatic pancreatic cancer: Is there a light at the end of the tunnel? World J Gastroenterol 2015; 21(16): 4788-4801 [PMID: 25944992 DOI: 10.3748/wjg.v21.i16.4788] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 44] [Article Influence: 6.4] [Reference Citation Analysis]
73 Kobayashi N, Shimamura T, Tokuhisa M, Goto A, Endo I, Ichikawa Y. Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure. Medicine (Baltimore). 2017;96:e6769. [PMID: 28489753 DOI: 10.1097/md.0000000000006769] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
74 Silvestris N, Longo V, Cellini F, Reni M, Bittoni A, Cataldo I, Partelli S, Falconi M, Scarpa A, Brunetti O, Lorusso V, Santini D, Morganti A, Valentini V, Cascinu S. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. Crit Rev Oncol Hematol 2016;98:309-24. [PMID: 26653573 DOI: 10.1016/j.critrevonc.2015.11.016] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
75 Cintas C, Douché T, Therville N, Arcucci S, Ramos-Delgado F, Basset C, Thibault B, Guillermet-Guibert J. Signal-Targeted Therapies and Resistance Mechanisms in Pancreatic Cancer: Future Developments Reside in Proteomics. Cancers (Basel) 2018;10:E174. [PMID: 29865155 DOI: 10.3390/cancers10060174] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
76 Kretz AL, von Karstedt S, Hillenbrand A, Henne-Bruns D, Knippschild U, Trauzold A, Lemke J. Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy. Cancers (Basel) 2018;10:E77. [PMID: 29562636 DOI: 10.3390/cancers10030077] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
77 Lakatos G, Petranyi A, Szűcs A, Nehéz L, Harsanyi L, Hegyi P, Bodoky G. Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience. Pathol Oncol Res 2017;23:753-9. [PMID: 28062950 DOI: 10.1007/s12253-016-0176-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
78 Napolitano F, Formisano L, Giardino A, Girelli R, Servetto A, Santaniello A, Foschini F, Marciano R, Mozzillo E, Carratù AC, Cascetta P, De Placido P, De Placido S, Bianco R. Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. Cancers (Basel) 2019;11:E981. [PMID: 31337045 DOI: 10.3390/cancers11070981] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
79 Auclin E, Marthey L, Abdallah R, Mas L, Francois E, Saint A, Cunha AS, Vienot A, Lecomte T, Hautefeuille V, de La Fouchardière C, Sarabi M, Ksontini F, Forestier J, Coriat R, Fabiano E, Leroy F, Williet N, Bachet JB, Tougeron D, Taieb J. Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. Br J Cancer 2021;124:1941-8. [PMID: 33772154 DOI: 10.1038/s41416-021-01341-w] [Reference Citation Analysis]
80 Li X, Ma T, Zhang Q, Chen YG, Guo CX, Shen YN, Sun PW, Li GG, Gao SL, Que RS, Lou JY, Yu RS, Yuan Y, Wei QC, Wei SM, Zhang Y, Zheng L, Bai XL, Liang TB. Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population. Cancer Lett. 2017;406:22-26. [PMID: 28729048 DOI: 10.1016/j.canlet.2017.07.012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
81 Suker M, Nuyttens JJ, Groot Koerkamp B, Eskens FALM, van Eijck CHJ. FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study. J Surg Oncol 2018;118:1021-6. [PMID: 30259526 DOI: 10.1002/jso.25233] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
82 Dhir M, Malhotra GK, Sohal DPS, Hein NA, Smith LM, O'Reilly EM, Bahary N, Are C. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. World J Surg Oncol. 2017;15:183. [PMID: 29017581 DOI: 10.1186/s12957-017-1240-2] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 13.0] [Reference Citation Analysis]
83 Javed MA, Beyer G, Le N, Vinci A, Wong H, Palmer D, Morgan RD, Lamarca A, Hubner RA, Valle JW, Alam S, Chowdhury S, Ma YT, Archibugi L, Capurso G, Maisonneuve P, Neesse A, Sund M, Schober M, Krug S. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Pancreatology. 2019;19:97-104. [PMID: 30529068 DOI: 10.1016/j.pan.2018.10.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
84 Berger AK, Singh HM, Werft W, Muckenhuber A, Sprick MR, Trumpp A, Weichert W, Jäger D, Springfeld C. High prevalence of incidental and symptomatic venous thromboembolic events in patients with advanced pancreatic cancer under palliative chemotherapy: A retrospective cohort study. Pancreatology 2017;17:629-34. [DOI: 10.1016/j.pan.2017.04.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
85 Blakaj A, Stein SM, Khan SA, Johung KL. Review and current state of radiation therapy for locally advanced pancreatic adenocarcinoma. J Gastrointest Oncol 2018;9:1027-36. [PMID: 30603121 DOI: 10.21037/jgo.2018.03.07] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
86 Salem AI, Alfi M, Winslow E, Cho CS, Weber SM. Has survival following pancreaticoduodenectomy for pancreas adenocarcinoma improved over time? J Surg Oncol 2015;112:643-9. [PMID: 26388048 DOI: 10.1002/jso.24048] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
87 O Kane GM, Knox JJ. Locally advanced pancreatic cancer: An emerging entity. Curr Probl Cancer 2018;42:12-25. [PMID: 29153290 DOI: 10.1016/j.currproblcancer.2017.10.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
88 Hackert T, Ulrich A, Büchler MW. Borderline resectable pancreatic cancer. Cancer Lett 2016;375:231-7. [PMID: 26970276 DOI: 10.1016/j.canlet.2016.02.039] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
89 Bednar F, Zenati MS, Steve J, Winters S, Ocuin LM, Bahary N, Hogg ME, Zeh HJ 3rd, Zureikat AH. Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes? Ann Surg Oncol 2017;24:1406-13. [PMID: 27896518 DOI: 10.1245/s10434-016-5707-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
90 Waghray M, Yalamanchili M, di Magliano MP, Simeone DM. Deciphering the role of stroma in pancreatic cancer. Curr Opin Gastroenterol. 2013;29:537-543. [PMID: 23892539 DOI: 10.1097/mog.0b013e328363affe] [Cited by in Crossref: 76] [Cited by in F6Publishing: 61] [Article Influence: 9.5] [Reference Citation Analysis]
91 Alemi F, Alseidi A, Scott Helton W, Rocha FG. Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma. Curr Probl Surg 2015;52:362-98. [PMID: 26363649 DOI: 10.1067/j.cpsurg.2015.07.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]